Company NameKyowa Hakko Kirin Co., Ltd.RepresentativeMasashi Miyamoto, President and COO<br/>(Code No. 4151, First Section of TSE)InquiriesTomoko Kashiwabara, Director,<br/>Corporate Communications Department<br/>Media Contact: +81-3-5205-7205<br/>Investor Contact: +81-3-5205-7206

# Kyowa Hakko Kirin Announces Changes in the Executive Directors

**Tokyo, February 5, 2019** – Kyowa Hakko Kirin Co., Ltd. (Headquarters: Tokyo; President and COO: Masashi Miyamoto, hereinafter, "Kyowa Hakko Kirin") here by announces that it resolved the following changes in its Executive Directors at its Board of Directors meeting held today.

The changes will be formally approved in the 96th Ordinary General Meeting of Shareholders to be held on March 2019 and the Board of Directors meeting after the General Meeting of Shareholders.

#### 1. The reason for the change

Bearing in mind Kyowa Hakko Kirin's smooth progress in its initiatives aimed at evolving into a global specialty pharmaceutical company, it has been decided that now is an opportune time for Nobuo Hanai, who is presently serving as Executive Director of the Board, Chairman, to relinquish his representative authority. Kyowa Hakko Kirin will work toward further strengthening its corporate governance by entrusting a larger share of business execution to the management led by the President and better clarifying the role of the Chairman as one of supervising business execution. In line with these changes, Kyowa Hakko Kirin wishes to newly appoint Yutaka Osawa, who is presently serving as Director of the Board, Managing Executive Officer, to the position of Director of the Board, Vice President, and grant him representative authority.

### 2. Details of the change

Nominee for a new Executive Director

New Position	Current Position	Name
Executive Director of the Board, Executive Vice President* (In charge of Internal Audit Department)	Director of the Board Managing Executive Officer Vice President Head, Production Division (In charge of Procurement Department)	Yutaka Osawa

Note that Masashi Miyamoto who is presently serving as Executive Director of the Board, President and COO will be appointed as Executive Director of the Board, President and CEO\*.

In addition, Nobuo Hanai who is presently serving as Executive Director of the Board, Chairman and CEO will be appointed as Director of the Board, Chairman\* without representative authority.

\* Concurrently serves as Executive Officer

#### 3. The date to be appointed

The day of the Ordinary General Meeting of Shareholders to be held in March 2019

## Nominee for a new Executive Director

Yutaka Osawa

Birthplace: Date of birth Education:	Graduated from the Master's degree course of Graduate School of Engineering from Tokyo Institute of Technology in March 1984	
Career sum Apr. 1984	Joined Kyowa Hakko Kogyo Co., Ltd.	
Apr. 1994 Apr. 1998	Manager, Pharmaceutical International Development Department, Kyowa Hakko Kogyo Co., Ltd.	
Jul. 1998	Manager, Pharmaceutical Development Center, Kyowa Hakko Kogyo Co., Ltd.	
Jun. 2000	Manager, Non-clinical Development Department, Kyowa Hakko Kogyo Co., Ltd.	
Jun. 2002	Seconded to KYOWA HAKKO U.K. LIMITED	
Aug. 2003	Seconded to KYOWA PHARMACEUTICAL, INC.	
Apr. 2007	Director, Pharmaceutical Production Development Department, Kyowa Hakko Kogyo Co., Ltd.	
Oct. 2008	Change of company name to Kyowa Hakko Kirin Co., Ltd. due to merger with Kirin Pharma Company, Limited	
	Director, CMC Development Department, Development Division, Kyowa Hakko Kirin Co., Ltd.	
Apr. 2009	Director, Production Planning Department, Production Division, Kyowa Hakko Kirin Co., Ltd.	
Mar. 2013	Executive Officer, Director, Production Planning Department, Production Division, Kyowa Hakko Kirin Co., Ltd.	
Apr. 2014	Executive Officer, Vice President Head, Production Division, Kyowa Hakko Kirin Co., Ltd.	
Mar. 2017	Managing Executive Officer, Vice President Head, Production Division, Kyowa Hakko Kirin Co., Ltd.	
Mar. 2018	Director of the Board, Managing Executive Officer, Vice President Head, Production Division (current)	

Number of shares of the company held by the candidate: 20,800 shares